58.40Open58.40Pre Close0 Volume10 Open Interest180.00Strike Price0.00Turnover6163.21%IV-3.20%PremiumJan 17, 2025Expiry Date66.27Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9870Delta0.0009Gamma3.70Leverage Ratio-266.8254Theta0.0000Rho3.65Eff Leverage0.0002Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet